The second Affiliated Hospital of Guangzhou Medical University

Guangzhou 510261

9 studies enrolling now · 12 studies all time

What they study most

Alzheimers Disease, Colitis, Ulcerative, Crohn Disease, Dravet Syndrome, Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention, Lipoprotein Disorder, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Relapsing Multiple Sclerosis

Studies at this site

• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome — Recruiting now
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) — Recruiting now
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling